INTRODUCTION AND OBJECTIVES: Transcatheter aortic valve implantation (TAVI) is a safe and effective alternative to surgical treatment in patients with severe aortic stenosis (AS) and those who are inoperable or at high surgical risk. The primary objective of this study was to evaluate the long-term survival of consecutive patients with severe AS treated with TAVI. METHODS: Observational, multicenter, prospective, follow-up study of consecutive patients with severe symptomatic AS treated by TAVI in 3 high-volume hospitals in Spain. RESULTS: We recruited 108 patients, treated with a self-expanding CoreValve prosthesis. The mean age at implantation was 78.6 ± 6.7 years, 49 (45.4%) were male and the mean logistic EuroSCORE was 16% ± 13.9%. The median follow-up was 6.1 years (2232 days). Survival rates at the end of years 1, 2, 3, 4, 5, and 6 were 84.3% (92.6% after hospitalization), 77.8%, 72.2%, 66.7%, 58.3%, and 52.8%. During follow-up, 71 patients (65.7%) died, 18 (25.3%) due to cardiac causes. Most (82.5%) survivors were in New York Heart Association class I or II. Six patients (5.5%) developed prosthetic valve dysfunction. CONCLUSIONS: Long-term survival in AS patients after TAVI is acceptable. The main causes of death are cardiovascular in the first year and noncardiac causes in subsequent years. Valve function is maintained over time.
INTRODUCTION AND OBJECTIVES: Transcatheter aortic valve implantation (TAVI) is a safe and effective alternative to surgical treatment in patients with severe aortic stenosis (AS) and those who are inoperable or at high surgical risk. The primary objective of this study was to evaluate the long-term survival of consecutive patients with severe AS treated with TAVI. METHODS: Observational, multicenter, prospective, follow-up study of consecutive patients with severe symptomatic AS treated by TAVI in 3 high-volume hospitals in Spain. RESULTS: We recruited 108 patients, treated with a self-expanding CoreValve prosthesis. The mean age at implantation was 78.6 ± 6.7 years, 49 (45.4%) were male and the mean logistic EuroSCORE was 16% ± 13.9%. The median follow-up was 6.1 years (2232 days). Survival rates at the end of years 1, 2, 3, 4, 5, and 6 were 84.3% (92.6% after hospitalization), 77.8%, 72.2%, 66.7%, 58.3%, and 52.8%. During follow-up, 71 patients (65.7%) died, 18 (25.3%) due to cardiac causes. Most (82.5%) survivors were in New York Heart Association class I or II. Six patients (5.5%) developed prosthetic valve dysfunction. CONCLUSIONS: Long-term survival in AS patients after TAVI is acceptable. The main causes of death are cardiovascular in the first year and noncardiac causes in subsequent years. Valve function is maintained over time.
Authors: Aida Ribera; John Slof; Ignacio Ferreira-González; Vicente Serra; Bruno García-Del Blanco; Purificació Cascant; Rut Andrea; Carlos Falces; Enrique Gutiérrez; Raquel Del Valle-Fernández; César Morís-de laTassa; Pedro Mota; Juan Francisco Oteo; Pilar Tornos; David García-Dorado Journal: Eur J Health Econ Date: 2017-11-23
Authors: Adam Chakos; Ashley Wilson-Smith; Sameer Arora; Tom C Nguyen; Abhijeet Dhoble; Giuseppe Tarantini; Matthias Thielmann; John P Vavalle; Daniel Wendt; Tristan D Yan; David H Tian Journal: Ann Cardiothorac Surg Date: 2017-09
Authors: Teresa Alvarado; Fernando Rivero; Guillermo Diego; Marcos García-Guimaraes; Jorge Salamanca; Pablo Díez-Villanueva; Javier Cuesta; Paula Antuña; Jesús Jiménez-Borreguero; Fernando Alfonso Journal: J Thorac Dis Date: 2021-07 Impact factor: 2.895
Authors: Marjo Jag De Ronde-Tillmans; Tom Aj de Jager; Jeannette A Goudzwaard; Nahid El Faquir; Nicolas M van Mieghem; Felix Zijlstra; Elisabeth Mwj Utens; Francesco Us Mattace-Raso; Mattie J Lenzen; Peter Pt de Jaegere Journal: J Geriatr Cardiol Date: 2018-04 Impact factor: 3.327
Authors: Marie-Isabel K Murray; Eileen Hofmann; Roberta De Rosa; Silvia Mas-Peiro; Philipp Seppelt; Thomas Walther; Andreas M Zeiher; Stephan Fichtlscherer; Mariuca Vasa-Nicotera Journal: J Interv Cardiol Date: 2019-10-01 Impact factor: 2.279